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The omission of outcomes that are of relevance to patients, clinicians and regulators across 
trials in autosomal dominant polycystic kidney disease (ADPKD) limits shared decision-
making. The Standardized Outcomes in Nephrology – Polycystic Kidney Disease (SONG-
PKD) Initiative convened an international consensus workshop on 25th October 2018, to 
discuss the identification and implementation of a potential core outcome set for all ADPKD 
trials. This article summarizes the discussion from the workshops and the SONG-PKD core 
outcome set. Key stakeholders including 11 patients/caregivers and 47 health professionals 
(nephrologists, policymakers, industry and researchers) attended the workshop. Four themes 
emerged: Relevance of trajectory and impact of kidney function included concerns about a 
patient’s prognosis and uncertainty of when they may need to commence kidney replacement 
therapy, and the lack of an early prognostic marker to inform long-term decisions; Discerning 
and defining pain specific to ADPKD highlighted the challenges in determining the origin of 
pain, adapting to the chronicity and repeated episodes of pain, the need to place emphasis on 
pain management and to have a validated measure for pain; Highlighting ADPKD 
consequences encompassed cyst-related complications and reflected patient’s knowledge 
because of family history and the hereditary nature of ADPKD; Risk of life-threatening but 
rare consequences such as cerebral aneurysm meant considering both frequency and severity 
of the outcome. Kidney function, mortality, cardiovascular disease and pain were established 










Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited 
cause of kidney failure, and is associated with an increased risk of mortality, cardiovascular 
disease, and stroke from ruptured cerebral aneurysms1,2. Patients with ADPKD have 
enlarging cysts involving the kidneys and often the liver, which can increase the weight of 
these organs by up to 20kg, leading to debilitating pain and impaired quality of life3,4. It is 
estimated that 50% of patients with ADPKD require kidney replacement therapy by the age 
of 70 years5,6. Patients have reported anxiety in seeing the impact of ADPKD on family 
members and having to confront disease progression and need for kidney replacement 
therapy2,7-9.  
 
Patients with ADPKD value outcomes that enable a “normal” lifestyle, including 
preservation of kidney function to avoid kidney replacement therapy, ability to work, 
maintenance of physical function, survival and minimization of pain7,9. However, these 
patient-important outcomes are reported in less than 20% of trials in ADPKD. The need for 
kidney replacement therapy and mortality were reported in only 13% and 9% of trials, 
respectively10-17. Moreover, cyst-related pain, which has been shown to be the most important 
patient-reported outcome to patients/caregivers9, was only reported in 22% of ADPKD 
trials17.  
 
Despite the impact that ADPKD has on patients’ abilities to work, physical function, mental 
health, and quality of life, patient-reported outcomes (PROs) are frequently omitted from trial 
reports. When they are reported, the measures used vary widely. For example, cyst pain had 
25 measures among 14 trials17. This makes it difficult to compare the effect of interventions 
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across trials. While there is increasing recognition and use of PROs in clinical trials, with 
regulators, including the U.S. Food and Drug Administration (FDA) recommending their 
inclusion in clinical research18,19, the selection and reporting of PROs for trials in ADPKD 
remain infrequent and inconsistent. 
 
In response to these problems with outcome reporting, the Standardized Outcomes in 
Nephrology (SONG) Initiative was established to develop core outcome sets that are 
critically important to all stakeholders including patients, caregivers and health professionals, 
to ensure trials consistently report critically important outcomes20-22. The core outcomes are 
identified through a transparent consensus process based upon the Core Outcome Measures 
Effectiveness Trials (COMET) and Outcome Measures in Rheumatology (OMERACT) 
framework21. A core outcome set is defined as an agreed minimum set of standardized 
outcomes that must be measured and reported in all trials in a defined clinical population23. 
Researchers can add other outcomes that are relevant and important to the trial.   
 
The SONG-PKD initiative commenced in 2017 to develop a core outcome set to be reported 
in all trials in people with ADPKD9,24. We convened a stakeholder workshop to review and 
discuss proposed core outcome domains identified through a multi-stage process involving a 
systematic review, focus groups with nominal group technique, and an international Delphi 
Survey9,24,25. This report provides a summary of the discussions and input from the workshop 





SONG-PKD CONSENSUS WORKSHOP  
 
Overview and context 
 
The SONG-PKD consensus workshop was convened to elicit stakeholder perspectives on the 
potential core outcome set for ADPKD.  The proposed core outcomes were identified based 
upon interim results of an international, online, two-round Delphi survey that was completed 
by patients, caregivers and health professionals with experience or expertise in ADPKD25. 
From the Delphi survey of 603 patients/caregivers and 411 health professionals from 56 
countries (in which the importance of each outcome was rated using a 9-point Likert Scale), 
we identified outcomes with mean and median scores ³7 and those with ³70% of the 
participants in both stakeholder groups (patients/caregivers and health professionals) rating 
the outcome to be of critical importance (7-9). The proposed core outcomes presented at the 
workshop were: kidney function, end-stage kidney disease (ESKD, defined as need for 
kidney replacement therapy), kidney cyst size/growth, cerebral aneurysm, blood pressure, 
death, cardiovascular disease, kidney cyst pain/bleeding/infection, life participation and 
chronic pain. The detailed analysis and final results of the Delphi will be published 
separately25.  
 
Participants and contributors  
 
Patients with ADPKD, their caregivers and health professionals from a broad range of 
geographical practice locations, clinical and research experience, policy and industry were 
invited to attend the workshop. Patients/caregivers who attended the workshop received 




In total, 58 participants (11 patients/caregivers and 47 health professionals) attended the 
workshop. Patients/caregivers were from the United States (n=11). Health professionals were 
from 10 countries including the United States (n=19), Australia (n=14), Republic of Korea 
(n=4), United Kingdom (n=3), Canada (n=2), Germany (n=1), Netherlands (n=1), New 
Zealand (n=1), Spain (n=1) and Taiwan (n=1). Workshop contributors (n=53 from 13 
countries) were patients/caregivers and health professionals who provided feedback on the 
pre-workshop materials and preliminary report but were unable to attend the workshop in 
person. Health professionals were from diverse backgrounds and collectively represented 
knowledge and experience in clinical nephrology, genetics and research (basic science, 
clinical research, epidemiology, clinical trials, implementation research) in ADPKD. Some 
participants held leadership or advisory positions in national and international professional 
societies (e.g. International Society of Nephrology), research, policy, regulatory, funding, 
industry and consumer organizations, including the US Food and Drug Administration 
(FDA), National Institutes of Health (NIH), Kidney Disease: Improving Global Outcomes 
(KDIGO), National Health Service (NHS), and the PKD Foundation.   
 
Workshop Program and Materials  
 
The workshop was held on October 25, 2018, at a hotel function room in San Diego, 
California, USA. This coincided with the American Society of Nephrology’s Kidney Week 
Annual Conference 2018 to maximize attendance. The workshop program and materials, 
including interim results from the Delphi survey, were distributed to all participants one week 
in advance. During the workshop, an overview of the SONG-PKD process, preliminary 
results from interim analysis of the Delphi survey and a list of potential core outcomes were 
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presented. Participants were allocated to one of seven breakout groups, which included at 
least one patient/caregiver and varying representation of health professionals (according to 
geographical practice location, field of expertise, industry, policy, funder) with up to ten 
members to foster depth and breadth in the scope of discussion. Facilitators (A.T., T.G., J.S., 
J.C., G.R., A.V., Y.C) attended a briefing session and were provided with a question guide 
(Supplementary File 1) prior to the workshop. 
  
During the breakout discussion, facilitators asked participants to reflect and comment on the 
potential core outcomes identified in the SONG-PKD Delphi survey. Three to five core 
outcome domains were recommended as a core outcome set to ensure feasibility, and had to 
include at least one patient-reported outcome domain20. Therefore, we included questions 
about combining clinical outcomes (kidney function, ESKD, cerebral aneurysm, 
cardiovascular disease, cyst bleeding/infection/growth) and selection of PROs (cyst-related 
pain or chronic pain). At the conclusion of the breakout discussion, the Chair (G.R.) asked 
the nominated speaker from each group to provide a summary of their discussion.   
 
All breakout and plenary discussions were audiotaped and transcribed verbatim. Transcripts 
were entered into HyperRESEARCH (ResearchWare Inc, version 3.0) to enable coding and 
analysis of the data. Y.C. identified and coded concepts into themes, and the preliminary 
findings were discussed among the investigative team (A.T., B.S., C.L.) to ensure they 









Based on discussion from the workshop, four themes relating to the identification of the core 
outcome and consideration for implementation in ADPKD were identified. Selected 
quotations supporting each theme are provided in Box 1. Figure 1 shows the SONG-PKD 
core outcome domains. Box 2 provides a summary of recommendations based on the 
workshop discussions.   
 
Relevance of trajectory and impact of kidney function  
 
Deliberating between the journey and destination: Workshop participants confirmed that 
kidney function was of top priority because it was seen as a signal of disease progression and 
projected onset of kidney failure, requiring kidney replacement therapy. Patients mentioned 
that the need for kidney replacement therapy (in particular dialysis) was ultimately the worst 
outcome that they feared. They wanted to “put off [dialysis] as long as possible because… 
that would be a big change of life” and “represented loss of hope.”  Moreover, participants 
agreed that “decline in kidney function,” expressed as a downward slope of trajectory, was 
much more powerful in informing anticipated onset of dialysis, rather than a snapshot of 
kidney function.   
 
Lacking a practical early marker for progression: Some health professionals were concerned 
about delayed manifestation of clinically evident decline in kidney function and emphasized 
the importance of “kidney volume change” as early “evidence that the disease is changing.” 
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They noted that this was particularly relevant because of the increasing availability of disease 
modifying medications. Regional variation in practice with regards to monitoring kidney size 
using imaging was evident, ranging from a lack of monitoring in Australia and New Zealand, 
to a broad range of routine radiology investigations in the USA. However, participants agreed 
that the relevance of kidney size or volume “depended on the stage of kidney disease” and 
expressed uncertainty about the feasibility of implementing measurement of kidney 
size/volume in all trials in ADPKD globally (considering practicality, cost, time burden) as 
clinicians “wouldn’t want to have a patient be assessed with imaging for every study.” 
 
Discerning and defining pain specific to ADPKD 
 
Indistinguishable and unpredictable: Participants reflected on the high priority given to pain-
related outcomes in the results of the Delphi survey25, including chronic pain and cyst pain 
related to cyst growth, bleeding and infection. Participants agreed it was “impossible to 
distinguish between different sources of pain,” and often patients and healthcare providers 
“don’t understand why there is pain,” particularly for chronic pain. One patient explained that 
they suffered from “back pain… that might be kidney related, but it’s actually back pain.” 
Because the source of pain is often poorly understood (particularly for chronic pain), 
participants proposed that “pain” should be a core outcome domain as it was difficult to 
ascertain if pain originated from the “cysts.”   
 
Adaptation to new threshold: The chronicity and repeated episodes of pain meant that some 
patients “get used to it and say oh, it’s just discomfort, it’s not really pain.”  They 
acknowledged the profound and broader consequences of pain on the patients’ functioning 
and daily activities, “the pain ends up having so many downstream effects on active, daily 
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living like ability to work, ability to do so many things,” and therefore “captures a lot more 
than just pain.”   
 
Bringing pain to prominence: Health professionals acknowledged that pain was often under-
recognized and inadequately managed because “there aren’t very good treatments for pain, 
and so they [patients] kind of give up mentioning it because it’s futile.” They remarked that 
the limited time available for consultation was focussed on other clinical priorities, such as 
blood pressure, even though pain has significant impact on functional capacity. Although 
patients wanted to enjoy life free of pain, they were often reluctant to discuss pain because 
they thought they were “going to be treated differently” among their social or professional 
network.   
 
Need for a consistent and validated measure: Although pain was regarded as a critically 
important outcome, participants felt it would be challenging to “capture it” in a way to 
accurately identify source and severity. They noted the lack of a validated tool with “good 
metrics about how to categorize and specify pain,” and suggested the need for a validated 
measure for pain in patients with ADPKD.    
 
Highlighting ADPKD consequences  
 
Complications of cyst growth: Participants considered whether kidney cyst infection, 
bleeding and cyst growth should be ‘core outcome domains.’ Some patients with “huge 
cysts” did not consider “growth” to be “important” as it did not affect their “daily life” 
whereas other cyst-related complications, such as “infection,” were critical because “it almost 
killed  me [patient].” Other participants considered “cyst infection and cyst bleeding…[to 
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be] ..not necessarily important every time.” Some health professionals focused on 
complications such as bleeding and infection as they were “all linked to cyst size and 
growth.”  
 
Heightened realization because of family history and hereditary nature: Health professionals 
commented that the priorities of patients with ADPKD from the Delphi survey appeared 
different compared to those of patients with chronic kidney disease from other causes. They 
remarked that patients with ADPKD seemed to be “incredibly well-informed…,” possibly 
influenced by the familial nature of ADPKD where “a lot of it has gone on for generations.” 
For example, “most people with polycystic kidneys have had experience with dialysis from a 
family member, whereas people who have other forms of kidney disease don’t actually know 
what’s going to happen to them, so they’re not quite so aware of all the issues and limitations 
that dialysis brings.” Patients supported including cardiovascular disease and mortality in the 
core outcome set because they were worried that their children would be at risk of premature 
death from cardiovascular disease and kidney failure. 
 
Risk of life-threatening but rare consequences  
 
Trying to make connections between outcomes: Participants discussed whether cerebral 
aneurysm should be captured within the outcome domain of cardiovascular disease. Health 
professionals strongly opposed combining cerebral aneurysm and cardiovascular disease as 
they were regarded as “a separate entity” driven by “different biologies.”  Moreover, “the 
typical cardiovascular protection doesn't come with the aneurysm protection” whereas they 
could easily accept that “cardiovascular disease [I can see] is linked to hypertension.” 
Cardiovascular disease was considered by participants as relevant to “kidney disease of any 
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sort, whether it’s ADPKD or diabetic kidney disease” and closely related to “progression of 
[kidney] disease.”  
 
Uncommon occurrence of cerebral aneurysm: Cerebral aneurysm was an outcome “patients 
care a lot about” and feared because “when it happens it’s devastating.” Some patients from 
the workshop were surprised at the high prioritization in the Delphi survey because it 
reflected “existential fear” that they have not experienced personally or through “family 
history.”  Health professionals, particularly researchers were hesitant about including cerebral 
aneurysm as a core outcome because it was a “very, very, very rare event,” and therefore not 
of critical importance to all ADPKD patients.   
 
POST-WORKSHOP CONSULTATION  
 
All workshop participants, including non-attending contributors, were provided with the draft 
workshop report for comment and approval. The SONG-PKD core outcome set (Figure 1) 
was reviewed by all participants, and was uploaded on the SONG website for feedback and 
comment (https://songiniative.org/projects/song-pkd/). We incorporated the feedback 




Patients with ADPKD, their caregivers and health professionals who contributed to this 
workshop report agreed that a core outcome set for ADPKD should include kidney function, 
mortality, pain and cardiovascular disease, based on their importance to decision-making. 
Kidney function was the foremost priority for all stakeholders, because it indicated the 
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potential need for kidney replacement therapy, the most feared consequence among patients 
with ADPKD. As such, patients with ADPKD preferred kidney function to be described as a 
change in function over time to estimate when they may need to commence dialysis. 
Mortality and cardiovascular disease were deemed acceptable as core outcome domains by 
participants due to their frequency, devastating consequence and direct relevance to all 
patients with ADPKD.  
 
In the Delphi survey25, outcomes related to pain, including cyst pain from growth, bleeding, 
infection and chronic pain, were highly prioritized due to their impact on life participation 
(e.g. ability to work, activities of daily living). The under-recognition of the chronicity of 
pain from ADPKD and a lack of effective treatment options in clinical settings were 
emphasized. All stakeholder groups agreed that pain was of central importance but were 
uncertain about identifying the source of pain. Hence, the participants recommended to 
change ‘cyst pain’ to ‘pain’ to be included as a core outcome domain. A recent study with 
patients and clinicians in the United States, Europe and Japan found that ADPKD-related 
pain was the most important outcome impacting physical functioning, with complex and 
distinctive presentations ranging from feeling full/discomfort to acute sharp pain. The 
Autosomal Dominant Polycystic Kidney Disease Impact Scale (ADPKD-IS), is a measure 
that was developed to assess the impact of ADPKD on health-related quality of life, and 
examines the overall symptom burden26. Although the ADPKD-IS includes questions specific 
to ADPKD-related pain, the investigators recommended further evaluation due to the 
complexity of pain. The workshop contributors also indicated the need for valid and relevant 




Kidney cyst size/volume was debated because of differences in practice patterns across 
regions whereby monitoring of kidney size was routine in the United States, and in other 
countries it was either not routinely done or not available. This was challenging because total 
kidney volume (TKV) is a prognostic biomarker for use in clinical trials for ADPKD recently 
qualified by the FDA27 and the European Medicines Agency (EMA), and use of tolvaptan 
was approved based on changes in TKV by the FDA, Health Canada and the Pharmaceuticals 
and Medical Devices Agency of Japan28. However, because its main applicability being 
limited to stages of ADPKD prior to decline in kidney function and recognition that it would 
not be necessary to mandate its measurement in all ADPKD trials, it was not included as part 
of the core outcome set, and instead was positioned in the middle tier of the core outcome set 
(Figure 1). Similarly, rupture of cerebral aneurysm was considered important but not 
universally relevant due to infrequent occurrence and therefore was not included as part of 
the core outcome set.  
 
The discussions from this workshop were used to establish the core outcome domains to be 
reported in trials in patients with ADPKD (Figure 1). Although the workshop involved 111 
collaborators from 17 countries, only US patients/caregivers participated in the in-person 
workshop, which may limit generalizability of findings. The next step will be to develop the 
core outcome measures for each of these outcome domains informed by the 
recommendations from this workshop (Box 2). For the patient-reported outcome of pain, we 
will follow the Consensus-based Standards for the selection of Health Measurement 
Instruments-Core Outcome Measures in Effectiveness Trials (COSMIN-COMET) 
process29,30. This will involve systematic reviews and consensus workshops with patients 
with ADPKD, their caregivers and health professionals to ensure content validity of the 
measure. Pilot and validations studies will follow to ensure that the measure is appropriate, 
 
 17 
psychometrically robust and feasible to be implemented in patients with ADPKD. 
Implementation of core outcomes in addition to outcomes of interest to study investigators in 
ADPKD trials is expected to enhance shared decision making for patients and health 
professionals, and ultimately improve outcomes that are critically important to patients with 
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Box 1. Selected quotations from the workshop discussions to illustrate each theme.  
Theme Quotations 





“I think that kidney function overall would be more important, because that’s what we’re 
trying to prolong in the long fight against the disease, prolong our kidney function as long as 
possible.” [G1, Patient] 
“End-stage kidney disease is, yeah, it’s something I would like to put off as long as possible 
because I know that that would be a big change of life for me, from being active and 
working full time and doing the things that I do. Also all the things that can come with end-
stage kidney disease, it’s a scary thought when you watch somebody go through that and 
they lose their thought processes and their cognitive skills. You’re like, I don’t want to be 
that. It’s scary.”  [G2, Patient]. 
“What that represents to me and what I hear patients tell me about is it represents loss of 
hope.” [G2, Health Professional] 
“I think the point is not kidney function or ESKD, I think it’s progression of decline.” [G2, 
Health Professional]. 
“They don’t want end-stage kidney disease but you can’t get there unless you have decline 
in kidney function, so I think that the objective is to prevent the decline in kidney function 





“I think it’s unique evidence that we have in this kidney disease, how kidney volume 
changes and size changes. We don’t have this ability to do in any of the kidney diseases, 
this is primary evidence that the disease is changing, that we have a modifying disease 
drug.” [G1, Health Professional]. 
“I think it also depends on the stage of kidney disease, because I think the kidney size is 
more important in younger patients where renal function isn’t really indicative of 
progression, whereas in the late stage you might get away with just using renal function.” 
[G1, Health Professional]. 
“we wouldn’t want to have a patient be assessed with imaging for every study. It was 
decided that perhaps it should be an important outcome but kept to the second level of the 
outcomes.” [G2, Health Professional].  




“..often the pain occurs really early on so when patients are still teenagers, when the 
kidneys are quite small relatively speaking still. We don’t understand why there is pain.” 
[G2, Health Professional]   
“…there’s really several different types of pain and pain – not even kidney pain, because it’s 
the other organs that are getting smushed.” [G2, Health Professional].  
“..I think a lot of people cannot specify if it’s from the cyst or if it’s from the lower back.” [G4, 
Health Professional].  
“Back pain because of changes in body center of gravity. That might be kidney related, but 
it’s actually back pain.” [G7, Health Professional]. 
Adaptation to 
new threshold 
“I may have pain, but it’s something I live with everyday so it’s not something that I can’t 
handle. Whereas someone that just had it, it would probably be something life-changing for 
them that they wouldn’t be able to deal with.” [G2, Patient]. 
“Pain is a problem, and it’s not just the pain. The pain ends up having so many downstream 
effects on active, daily living like ability to work, ability to do so many things. I think that 
captures a lot more than just pain.” [G5, Health Professional] 
“Become used to it. You become used to it, so you don’t think of it as pain.” [G7, Patient]. 
“The early stages you may recognize something as painful and then get used to it and say 
oh, it’s just discomfort, it’s not really pain.” [G7, Health Professional] 
Bringing pain to 
prominence 
“If someone finds that they have the disease process, they feel like they’re going to be 
treated differently, that they have a deficit of some kind, like oh, they can’t do that. They 
don’t want people to know it.” [G2, Health Professional] 
“They complain, and if they get dismissed then they learn how to manage what’s going to 




“There aren’t very good treatments for pain, and so they kind of give up mentioning it 
because it’s futile and it takes up time in a consultation and the end result is always the 
same.” [G2, Health Professional] 




“Pain is a really good outcome, a very important outcome.  The challenge is how to capture 
it.” [G2, Health Professional]  
“..pain was a very important domain, that it should be included in the core outcomes, but 
perhaps not only cyst pain or acute pain or chronic pain, but just pain as a global domain 
and then there should be a good measurement and toolkit to have good metrics about how 
to categorize and specify pain in studies.” [G2, Health Professional].  
“Pain is not a single entity but it’s a constellation and has to be better addressed.” [G5, 
Health Professional] 
Highlighting ADPKD consequences  
Complications of 
cyst growth 
“Just knowing what I’ve learnt over the years is that we don’t see a lot of pain episodes in 
small kidneys, we don’t see a lot of bleeding or infection, infection sometimes but… and 
they’re all linked to cyst size and growth.” [G1, Health Professional] 
“My personal opinion is that the cyst infection and cyst bleeding, that these are not 
necessarily important every time.” [G4, Health Professional] 
“Speaking from a patient who has huge cysts and no symptoms, growth is not important to 
me. I know that it impacts function, but in my daily life? Doesn’t matter. Infection definitely 








“Because a lot of it has gone on for generations.” [G1, Health Professional] 
“This list looks like a group of incredibly well-informed patients. They’ve been well-educated 
by their doctors to tell them that blood pressure is important, that cardiovascular disease is 
important, and dialysis is important, kidney function is important.  It doesn’t sound like ‘how 
do I feel differently every day’.  It’s such a different patient group than other chronic kidney 
disease patients.” [G1, Health Professional]  
“.. it’s a scary thought when you watch somebody go through that and they lose their 
thought processes and their cognitive skills. I don’t want to be that. It’s scary.” [G2, Patient] 
“..My sister is on dialysis.” [G5, Patient] 
“..most people with polycystic kidneys have had experience with dialysis from a family 
member, whereas people who have other forms of kidney disease don’t actually know 
what’s going to happen to them, so they’re not quite so aware of all the issues and 
limitations that dialysis brings. But a lot of patients that I see also worry about their 
children’s future.” [G7, Health Professional] 
Risk of life-threatening but rare consequences 




“..they’re two quite different diseases and quite different biologies. Cardiovascular disease 
and cerebral aneurysm. I don’t think that they should be collapsed together because 
collapsing them together, they have different interventions, different processes,” [G3, Health 
Professional] 
“Cardiovascular disease in kidney disease of any sort, whether it’s PKD or diabetic kidney 
disease, is usually a progression of disease and all your risk factors. You could have 
cerebral aneurysm without having significant kidney function decline.” [G5, Health 
Professional]. 
“The typical cardiovascular protection doesn’t come with the aneurysms protection.” [G6, 
Health Professional]  





“It’s what every patient worries about, right? Because when it happens it’s devastating, so 
people know about it a lot. It’s not something that anyone in a trial would be focusing on, 
because it’s not very common. It also requires fairly extensive imaging.” [G1, Health 
Professional]  
“I was surprised that cerebral aneurysm, even though it’s not top four, is up there. Because 
that seems sort of an existential fear that I certainly never had, maybe it’s because our 
family history doesn’t include it, but even for those families that do, they’re, what, 6% 
maybe?” [G3, Patient] 
“aneurysm rupture is actually quite rare.” [G3, Health Professional]  




Box 2. Key workshop recommendations for establishing and implementing core 
outcome domains for autosomal dominant polycystic kidney disease (ADPKD). 
Core outcome domains for ADPKD should: 
• Support ability to determine prognosis, particularly in terms of the need to commence kidney 
replacement therapy 
• Include clinical outcomes, such as cardiovascular disease, that have long-term implications to 
facilitate long-term planning  
• Be applicable for patients across all stages of kidney disease          
• Include outcomes that enable participation in daily activities and achievement of life goals, such 
as those related to study, work and family  
• Include pain in general terms (rather than ADPKD-pain) as it may not always be feasible to 
accurately identify the cause or source of pain 
Implementation of core outcomes requires: 
• Development of clinical measures that consider priorities of patients to support decision-
making, particularly about kidney replacement therapy  
• Measures that can be feasibly implemented in health care and research settings internationally  








Figure 1.  SONG-PKD core outcome domain shown as three circles representing the 
core outcomes (1), middle tier (2) and outer tier (3)
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